NCT00841087View on ClinicalTrials.gov

Comparison of NN1250 Versus Insulin Detemir, Both Combined With Insulin Aspart in Subjects With Type 1 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
DiabetesDiabetes Mellitus, Type 1
Interventions
DRUG

insulin degludec

The insulin NN1250 (insulin degludec) injected subcutaneously at bedtime

DRUG

insulin detemir

Injection subcutaneously at bedtime

DRUG

insulin aspart

Injection subcutaneously immediately before each meal.

Trial Locations (8)

103 0002

Novo Nordisk Investigational Site, Chuo-ku, Tokyo

243 0432

Novo Nordisk Investigational Site, Ebina-shi

963 8851

Novo Nordisk Investigational Site, Koriyama-shi, Fukushima

862 0976

Novo Nordisk Investigational Site, Kumamoto-shi,Kumamoto

870 0039

Novo Nordisk Investigational Site, Ōita

060 0062

Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido

062 0007

Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido

235 0045

Novo Nordisk Investigational Site, Yokohama

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY